Real-world use of anti-CGRP medicines for preventing migraine

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a 2-year multicenter observational project that follows patients prescribed anti-CGRP monoclonal antibodies or gepants under routine care. Participants undergo a baseline assessment when treatment starts and return every six months to record treatment effectiveness, side effects, patient-reported outcome measures, and ongoing eligibility for the medication. Inclusion depends on a migraine diagnosis (ICHD-III) and meeting local prescriber and reimbursement criteria, with consent obtained before enrollment. No experimental interventions are assigned — treatments are given per clinicians' decisions and the study collects real-world data to compare outcomes across different anti-CGRP options.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Migraine diagnosis according to ICHD-III.
* Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations.
* Signature of informed consent.

Exclusion Criteria:

* Presence of headache different from migraine.
* Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study.

Where it's running

• University of Miami, Miller School of Medicine
  Miami, Florida, United States Recruiting
• Fleni
  Buenos Aires, Argentina Recruiting
• Pontificia Universidad Católica de Chile
  Santiago, Chile Recruiting
• Neuromedica
  Medellín, Colombia Recruiting
• Special Hospital for Orthopedics and Rehabilitation "Martin Horvat" Rovinj-Rovigno
  Rovinj, Croatia Recruiting
• Charité Universitätsmedizin Berlin
  Berlin, Germany Recruiting

Study contacts

• Principal investigator: Patricia Pozo-Rosich, MD, PhD — Vall d'Hebron University Hospital
• Study coordinator: Patricia Pozo-Rosich, MD, PhD
• Email: cefalea@vhir.org
• Phone: (+34) 93 489 30 00

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Analyzing CGRP Levels in Migraine Patients by Age and Sex

  This study looks at the levels of a substance linked to migraines in people with migraines and healthy individuals to see how age and sex might affect treatment responses.

  Recruiting Hospital Universitari Vall d'Hebron Research Institute · Barcelona, Barcelona · NCT06674772

• MMA Embolization for Migraine: Patient-Reported Outcomes from a Single Site

  This registry tests whether adults with migraine who have or plan to have middle meningeal artery embolization notice changes in headaches and quality of life over time.

  Recruiting Cortex Neurovascular · Tacoma, Washington · NCT07652034

• Bilateral middle meningeal artery embolization for refractory chronic migraine

  This study will try blocking both middle meningeal arteries with Onyx in adults who have refractory bilateral chronic migraine to see if it is safe and lowers headaches.

  Recruiting Johns Hopkins University · Baltimore, Maryland · NCT07223008

• New methods to test preventive migraine treatment

  This trial will test how the active medicine, placebo injections, and the information given about them affect symptoms in adults with chronic migraine.

  Recruiting at 2 sites University of Aarhus · Aarhus C, Denmark and 1 other locations · NCT07071506

• Nordic comparison of CGRP antibody plus onabotulinumtoxinA (Botox) versus CGRP antibody alone for chronic migraine

  This trial will test whether adding onabotulinumtoxinA (Botox) to a CGRP monoclonal antibody reduces monthly headache days in adults with chronic migraine.

  Recruiting Phase 3 Oslo University Hospital · Grålum and 5 other locations · NCT07040813

• Assessing the safety and effectiveness of Atogepant for migraine prevention in Korean adults

  This study is testing how well and safely Atogepant works for preventing migraines in Korean adults who have chronic or episodic migraines.

  Recruiting at 36 sites AbbVie · Busan, Busan Gwang Yeogsi and 35 other locations · NCT06603558

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.